AGM results: all 3 resolutions pass with over 99.99 percent support

Board & Shareholder Meetings View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹69.90

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.3%+0.0% vs market

Pharmaceuticals peers, median of 173sector-0.8%-0.5% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3-1.3+0.0-0.8-0.5

Next day

+2.1-1.3+3.4-1.3+3.3

-0.1+0.0-0.2-0.4+0.3

-1.4-0.2-1.2-0.1-1.3

-0.4-3.0+2.6-3.1+2.7

-2.6-2.7+0.1-3.1+0.5

-5.6-1.7-3.9-3.0-2.6

15d

-5.6-8.9+3.2-7.1+1.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Astal Laboratories held its 33rd AGM on September 29, 2026 via video conferencing. Three ordinary resolutions were voted on: adoption of standalone FY2026 financials (passed with 99.99999 percent in favor), adoption of consolidated FY2026 financials (passed with 99.99999 percent in favor), and re-appointment of Non-Executive Director Mr. Maggidi Venkatesh via retirement by rotation (passed with 99.99941 percent in favor). Out of 3,436 shareholders on record date, about 46.46 percent of outstanding shares participated in voting. Scrutinizer Mahendra Prakash Khandelwal confirmed all resolutions were passed with requisite majority.

Likely market impact

Routine procedural filing. All resolutions passed comfortably with near-unanimous support, indicating no shareholder dissent or governance concerns. Neutral for stock price.